Section Arrow
GKOS.NYSE
- Glaukos Corp
Quotes are at least 15-min delayed:2025/12/08 19:16 EST
After Hours
Last
 108.46
0 (0.00%)
Bid
75.8
Ask
125.25
High 108.46 
Low 108.17 
Volume 21.44K 
Regular Hours (Closed)
Last
 108.46
-0.05 (-0.05%)
Day High 
109.74 
Prev. Close
108.51 
1-M High
112 
Volume 
642.43K 
Bid
75.8
Ask
125.25
Day Low
107.28 
Open
109.45 
1-M Low
80.905 
Market Cap 
6.23B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 105.07 
20-SMA 97.95 
50-SMA 88.78 
52-W High 163.71 
52-W Low 73.16 
Exchange NYSE 
Valuation Estimation
EPS (Current/Estimated)
-1.54/0.05
Enterprise Value
6.34B
Balance Sheet
Book Value Per Share
13.40
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
383.48M
Operating Revenue Per Share
5.29
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PFSAProfusa Inc0.1984+0.0214+12.09%-- 
After Hours 0.1962 -0.0022 -1.11%
BSXBoston Scientific Corp93.84-3.68-3.77%52.15PE
After Hours 93.9 +0.06 +0.06%
BFLYButterfly Network3.14+0.08+2.61%-- 
After Hours 3.12 -0.02 -0.64%
ABTAbbott Laboratories122.09-2.99-2.39%15.71PE
After Hours 122.29 +0.2 +0.16%
WOKWORK Medical Technology Group LTD.4.85-0.38-7.27%-- 
After Hours 4.85 0 0.00%
Industry overview quotes are at least 15 minutes delayed
Business Description
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.